
    
      Subjects to receive one injection with NT 201 or placebo at baseline of the
      placebo-controlled first cycle. Thereafter, all subjects entering the Open-Label Extension
      Period (OLEX) to receive a second injection of NT 201 (second injection cycle).
    
  